PROTEOMIC OF CANCER: ISOFORMS OF ALTERNATIVE SPLICING AS POTENTIAL MOLECULAR BIOMARKERS OF TUMORAL TISSUES

Lívia Cavalcanti de Morais Gama; João Carlos Setubal; Rodrigo Fernandes Ramalho

All Papers

Submission

Paper Title

PROTEOMIC OF CANCER: ISOFORMS OF ALTERNATIVE SPLICING AS POTENTIAL MOLECULAR BIOMARKERS OF TUMORAL TISSUES

Authors

Lívia Cavalcanti de Morais Gama
João Carlos Setubal
Rodrigo Fernandes Ramalho

Modality

Poster

Subject area

Proteins and Proteomics

Publishing Date

08/11/2023

Country of Publishing

Brazil | Brasil

Language of Publishing

Inglês

Paper Page

https://www.even3.com.br/anais/xmeeting2023/624772-proteomic-of-cancer--isoforms-of-alternative-splicing-as-potential-molecular-biomarkers-of-tumoral-tissues

ISBN

978-65-272-0061-1

Keywords

Alternative splicing, biomarkers, cancer, proteomics

Summary

Recent results have shown that Mass Spectrometry (MS) is capable of detecting proteins that differ from those described by reference annotation of human genome (called alternative proteins herein). The translation of a same mRNA through distinct reading frames or of distinct gene transcripts created by alternative splicing (AS) are examples of molecular process that results in alternative proteins. Although most proteomic studies detects, on average, only 30% of the ~20 thousand proteins of the human reference proteome, many found dozens or even hundreds of alternative proteins. In a previous work, we analyzed public data of AS events and MS experiments to identify 14 alternative proteins in diverse samples of normal tissues. Our result brought evidence of translation to certain alternative transcripts generated by exon skipping, the most common AS type in humans. In the present study, we investigate the presence of these 14 alternative proteins by searching 46,602,926 mass spectra, from PRIDE and CPTAC databases, comprising 37,691,084 spectra from five cancer types (colon, ovary, breast, liver and brain) as well as 8,911,842 from the respective normal tissues, with the aim to evaluate these proteins as potential cancer biomarkers. Among the 14 investigated genes, we identify seven (HNRNPAB, EPB41L3, PUF60, SPTAN1 e FN1, COL6A3 and CLIP1) with proteomic evidences of exon skipping on at least one cancer type. Here, we did not use a quantitative approach to analyze the MS data, therefore our conclusions are based on the presence or absence of reliable peptide-spectrum matches (PSMs) that characterize differential exon skipping events between normal and tumoral tissues. However, it is worth noting that for some AS events, the difference between PSMs counts was remarkable between normal and tumor tissues indicating a possible difference at the level of exon inclusion. With the improvement of MS technology, the investigation of splicing variants at protein level promises an increase in the discovery of molecular markers and therapeutic targets in cancer.

Title of the Event: X-Meeting / BSB 2023
City of the Event: Curitiba
Title of the Proceedings of the event: X-Meeting presentations
Name of the Publisher: Even3
Means of Dissemination: Meio Digital

How to cite

GAMA, Lívia Cavalcanti de Morais; SETUBAL, João Carlos; RAMALHO, Rodrigo Fernandes. PROTEOMIC OF CANCER: ISOFORMS OF ALTERNATIVE SPLICING AS POTENTIAL MOLECULAR BIOMARKERS OF TUMORAL TISSUES.. In: X-Meeting presentations. Anais...Curitiba(PR) Campus da indústria, 2023. Available in: https//www.even3.com.br/anais/xmeeting2023/624772-PROTEOMIC-OF-CANCER--ISOFORMS-OF-ALTERNATIVE-SPLICING-AS-POTENTIAL-MOLECULAR-BIOMARKERS-OF-TUMORAL-TISSUES. Access in: 22/06/2025